Oral bisphosphonate compliance and persistence: a matter of choice?
Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.
Silverman
S L
SL
Cedars-Sinai/UCLA/OMC, 8641 Wilshire Blvd., Suite 301, Beverly Hills, CA 90211, USA. stuarts@omcresearch.org
Schousboe
J T
JT
Gold
D T
DT
D001294:Attitude to Health; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D055118:Medication Adherence / Q000523:psychology*; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D004164:Diphosphonates
Diabetes Care. 2005 Feb;28(2):278-82
15677779
J Bone Miner Res. 2008 Sep;23(9):1435-41
18442318
BMJ. 2008 May 17;336(7653):1114-7
18480115
Osteoporos Int. 2003 Dec;14(12):965-8
14504697
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011
18425859
Osteoporos Int. 2007 Mar;18(3):271-7
17021945
Osteoporos Int. 2006;17(3):478-83
16283066
Curr Med Res Opin. 2006 Dec;22(12):2383-91
17257452
Curr Med Res Opin. 2007 Dec;23(12):3137-52
17988435
Osteoporos Int. 2006;17(11):1626-9
16823543
Health Serv Res. 2009 Oct;44(5 Pt 1):1640-61
19500161
Curr Opin Rheumatol. 2009 Jul;21(4):356-62
19412103
Int J Clin Pract. 2006 Aug;60(8):896-905
16800837
J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):58-63
18192132
Bone. 2009 Jan;44(1):153-9
18926939
Osteoporos Int. 2010 Jan;21(1):145-55
19459025
Osteoporos Int. 2009 Dec;20(12):2127-34
19499273
Telemed J E Health. 2009 Oct;15(8):770-6
19780692
Mayo Clin Proc. 2006 Aug;81(8):1013-22
16901023
Osteoporos Int. 2003 Jul;14(6):490-5
12730761
Med Decis Making. 2009 Jan-Feb;29(1):125-39
18566486
J Rheumatol. 2005 Jun;32(6):1086-92
15940773
Osteoporos Int. 2008 Jun;19(6):811-8
17999022
J Bone Miner Metab. 2010 Mar;28(2):176-84
19657590
Osteoporos Int. 2007 Aug;18(8):1023-31
17308956
JAMA. 2002 Jul 24-31;288(4):462-7
12132976
Maturitas. 2004 Jul 15;48(3):271-87
15207894
Int J Med Inform. 2009 Apr;78(4):230-8
18778967
J Clin Endocrinol Metab. 2007 Apr;92(4):1296-304
17244788
Bone. 2006 Jun;38(6):922-8
16330270
J Nerv Ment Dis. 1999 Oct;187(10):630-5
10535657
Maturitas. 2005 Mar 14;50(3):196-208
15734601
Int J Technol Assess Health Care. 1995 Summer;11(3):443-55
7591546
J Clin Endocrinol Metab. 2004 Mar;89(3):1117-23
15001596
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
18453793
Osteoporos Int. 2004 Dec;15(12):1003-8
15167989
Bone. 2006 Feb;38(2 Suppl 2):S18-21
16443406
Osteoporos Int. 2008 Jul;19(7):1029-37
18193329
Med Care. 2009 Mar;47(3):334-41
19194337
Curr Rheumatol Rep. 2008 Apr;10(2):118-22
18460266